Tesamorelin is FDA-approved for exactly one thing: reducing excess visceral fat in adults with HIV-associated lipodystrophy. No telehealth clinic prescribes it for anti-aging, and for age-related GH decline the drug patients actually receive is compounded sermorelin.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) approved by the FDA for one narrow use: reducing excess abdominal fat in HIV-infected adult patients with lipodystrophy [1]. It is not approved, and not sold by telehealth clinics, for anti-aging, general weight loss, or athletic performance. Most people searching for it are researching the growth hormone axis, and for age-related GH decline the drug that clinics actually prescribe is compounded sermorelin.
- Tesamorelin is a stabilized analog of the full 44-amino-acid GHRH peptide [1]
- Its only FDA-approved indication is excess abdominal fat in HIV-associated lipodystrophy [1]
- In phase 3 trials, visceral fat fell 15.2% and IGF-1 rose 81.0% over 26 weeks [2]
- It stimulates the pituitary to release GH. It does not deliver growth hormone directly [4]
- For age-related GH decline, telehealth clinics prescribe compounded sermorelin, not tesamorelin
What Tesamorelin Is
Tesamorelin is a GHRH analog. It reproduces the full 44-amino-acid sequence of human GHRH and adds an N-terminal modification that resists breakdown by dipeptidyl peptidase-4 [7], the enzyme that clears native GHRH within minutes. That single change extends its functional half-life and lets a once-daily injection produce a sustained signal.
The mechanism is upstream stimulation, not hormone replacement. Tesamorelin binds GHRH receptors in the anterior pituitary and prompts pulsatile GH release, and the liver converts that GH into IGF-1, the biomarker that tracks the effect [4]. Somatostatin feedback stays intact, so the pituitary is not suppressed and physiologic overshoot is limited at label doses.
- Binds GHRH receptors in the anterior pituitary
- Triggers the pituitary to release its own GH in pulses
- Liver converts GH into IGF-1, the measurable downstream marker
- Resists DPP-4 degradation, giving a longer functional half-life than native GHRH [7]
The One Thing It Is Approved For
Tesamorelin holds a single FDA indication: reducing excess abdominal fat in HIV-infected adult patients with lipodystrophy [1]. That population develops a distinct pattern of visceral fat accumulation linked to antiretroviral therapy, and tesamorelin was developed and approved specifically for it. The label does not extend to general obesity, subcutaneous fat, cosmetic body contouring, or anti-aging.
Any use of tesamorelin outside HIV-associated lipodystrophy is off-label. It is priced as a specialty injectable rather than a wellness subscription, which is one reason telehealth platforms offering GHRH therapy for age-related decline dispense compounded sermorelin instead.
Dosing and Administration
The approved regimen is 2 mg injected subcutaneously once daily [1]. Tesamorelin is supplied as a powder that is reconstituted before injection and rotated across abdominal sites. Response is assessed at about 6 months, and the label directs stopping treatment if a meaningful effect on visceral fat is not seen, because the benefit does not persist once the drug is discontinued [1].
How Tesamorelin Differs From Sermorelin
Both are GHRH analogs that act on the same receptor, so the difference is structural and regulatory rather than mechanistic. Sermorelin is GHRH(1-29), the shortest fragment of the parent molecule that keeps full biological activity [5]. Tesamorelin keeps the whole 44-amino-acid chain and stabilizes it.
| Property | Tesamorelin | Sermorelin |
|---|---|---|
| Structure | 44-amino-acid GHRH plus N-terminal modification [1] | GHRH(1-29), the shortest active fragment [5] |
| FDA status | Approved 2010, currently marketed [1] | No current approval; compounded only [5] |
| Approved indication | Excess abdominal fat in HIV lipodystrophy [1] | None currently |
| Evidence base | Large phase 3 trials [2][3] | Small adult trials; larger pediatric history [5][6] |
| How it is obtained | Commercial specialty prescription | Compounded via 503A or 503B pharmacy |
| Typical use | HIV-associated visceral fat | Age-related GH decline (off-label for all) |
Why Most People Asking Are Better Served by a Sermorelin Protocol
The practical answer to whether you should take tesamorelin is usually no, for reasons that have nothing to do with the molecule working. Tesamorelin is approved and priced for a specific medical population, and no legitimate telehealth clinic sells it for wellness goals. The GH-axis option available for age-related decline is compounded sermorelin.
Sermorelin works through the same GHRH receptor and raises IGF-1 through the same pathway. Its adult evidence is thinner. The closest controlled trial gave a norleucine-substituted GHRH(1-29) analog at 10 mcg/kg nightly to adults aged 55 to 71 and found IGF-1 elevation within 2 weeks, increased lean mass in men, and increased skin thickness in both sexes over 16 weeks [6]. It is not FDA-approved and it is not a weight-loss drug, but it is what a prescribing physician can legally and affordably provide for age-related GH decline.
Any legitimate GHRH protocol starts with a baseline IGF-1 and rechecks it at about 90 days. A program that moves from consultation to prescription without lab work is a consistent red flag, regardless of which peptide is on the label.
Tesamorelin is limited to HIV-associated lipodystrophy. For age-related GH decline, compounded sermorelin works through the same GHRH receptor, and SystemLabs includes a baseline IGF-1 before prescribing so you have a real starting point and a 90-day response to measure.
Who Tesamorelin Is Actually For
- Adults with HIV-associated lipodystrophy and excess visceral fat, the population it was approved and studied in [1][2]
- Patients under specialist care where the specialty cost is justified by the indication
- Not indicated for general weight loss, subcutaneous fat, or cosmetic goals
- Not FDA-approved for anti-aging, bodybuilding, or performance, and not sold by telehealth clinics for those uses
Side Effects and Cautions
The common adverse effects in trials were injection site reactions, joint pain, and peripheral edema, the pattern expected from raising GH and IGF-1 [4]. Glucose deserves attention because growth hormone opposes insulin, though pooled phase 3 data found no clinically meaningful difference in glucose parameters at 26 and 52 weeks [3]. The same cautions apply to sermorelin, which acts through the identical GH-axis pathway.
- Contraindicated in active malignancy, because IGF-1 elevation is the reason for monitoring [1]
- Not for use in pregnancy or with disruption of the pituitary-hypothalamic axis [1]
- Injection site reactions, arthralgia, and peripheral edema are the common effects [4]
- Glucose was neutral over a full course in pooled trials, but monitoring during the first 3 months is prudent [3]
Frequently Asked Questions
What is tesamorelin used for?
Tesamorelin is FDA-approved for one use: reducing excess abdominal fat in HIV-infected adults with lipodystrophy [1]. In that population it lowered visceral fat by about 15% over 26 weeks in phase 3 trials [2]. It is not approved for general weight loss, anti-aging, or athletic use, and prescribing it outside HIV-associated lipodystrophy is off-label.
Is tesamorelin the same as sermorelin?
No. Both are GHRH analogs that act on the same pituitary receptor, but tesamorelin keeps the full 44-amino-acid GHRH chain with a stabilizing modification [1], while sermorelin is the shorter GHRH(1-29) fragment [5]. Tesamorelin is FDA-approved and commercially manufactured. Sermorelin has no current approval and is compounded. For age-related GH decline, clinics prescribe sermorelin.
Can I get tesamorelin for anti-aging or weight loss?
Not from a legitimate program for those indications. Tesamorelin is approved only for HIV-associated lipodystrophy [1], it is priced as a specialty injectable, and telehealth platforms offering GHRH therapy for age-related decline dispense compounded sermorelin instead. Any tesamorelin use outside its label is off-label.
How does tesamorelin work?
Tesamorelin stimulates the pituitary rather than replacing growth hormone. It binds GHRH receptors, prompts pulsatile GH release, and the liver converts that GH into IGF-1 [4]. Its N-terminal modification resists the DPP-4 enzyme that clears native GHRH within minutes [7], which gives it a longer functional half-life and supports once-daily dosing.
Is tesamorelin FDA-approved?
Yes, but only for excess abdominal fat in HIV-infected adults with lipodystrophy [1]. That is its sole approved indication. Sermorelin, CJC-1295, and ipamorelin are not FDA-approved and are available only as compounded preparations. No GHRH analog is approved for anti-aging or general body composition.
References
- EGRIFTA SV (tesamorelin) for injection, for subcutaneous use: full prescribing information DailyMed, U.S. National Library of Medicine, 2010. Initial U.S. Approval: 2010. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224
- Metabolic effects of a growth hormone-releasing factor in patients with HIV New England Journal of Medicine, 2007. PMID: 18057338. https://pubmed.ncbi.nlm.nih.gov/18057338/
- Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data Journal of Clinical Endocrinology & Metabolism, 2010. PMID: 20554713. https://pubmed.ncbi.nlm.nih.gov/20554713/
- Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies Growth Hormone & IGF Research, 2015. PMID: 25555516. https://pubmed.ncbi.nlm.nih.gov/25555516/
- Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency BioDrugs, 1999. PMID: 18031173. https://pubmed.ncbi.nlm.nih.gov/18031173/
- Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women Journal of Clinical Endocrinology & Metabolism, 1997. PMID: 9141536. https://pubmed.ncbi.nlm.nih.gov/9141536/
- Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy HIV/AIDS (Auckland), 2011. PMID: 22096409. https://pubmed.ncbi.nlm.nih.gov/22096409/
